Douglas A. Bergman

Conformational Selection of Inhibitors and Substrates by Proteolytic Enzymes:  Implications for Drug Design and Polypeptide Processing

David P. Fairlie, Joel D. A. Tyndall, Robert C. Reid et al. · Journal of Medicinal Chemistry · 2000 · 152 citations · Full text

Protein Assembly, Biomolecular Structure Prediction, Molecular Biology +21

Substrate-Based Cyclic Peptidomimetics of Phe-Ile-Val That Inhibit HIV-1 Protease Using a Novel Enzyme-Binding Mode

Darren R. March, Giovanni Abbenante, Douglas A. Bergman et al. · Journal of the American Chemical Society · 1996 · 76 citations

Peptide Engineering, Molecular Biology, Peptide Substrates +20

Synthesis, Stability, Antiviral Activity, and Protease-Bound Structures of Substrate-Mimicking Constrained Macrocyclic Inhibitors of HIV-1 Protease

Joel D. A. Tyndall, Robert C. Reid, David Tyssen et al. · Journal of Medicinal Chemistry · 2000 · 66 citations · Full text

Immunology, Antiviral Drug, Immunotherapy +18

Regioselective structural and functional mimicry of peptides. Design of hydrolytically-stable cyclic peptidomimetic inhibitors of HIV-1 protease.

Giovanni Abbenante, Darren R. March, Douglas A. Bergman et al. · Journal of the American Chemical Society · 1995 · 58 citations

Peptide Engineering, Altmetric Attention Score, Peptide Science +16

A novel thioether linker: Chemical synthesis of a HIV-1 protease analogue by thioether ligation

Darren R. Englebretsen, B. Garnham, Douglas A. Bergman et al. · Tetrahedron Letters · 1995 · 54 citations

Medicinal Chemistry, Bioorganic Chemistry, Biochemistry +9